NDLI: SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic

Content Provider	Springer Nature : BioMed Central
Author	Rabaan, Ali A. Al-Ahmed, Shamsah H. Sah, Ranjit Tiwari, Ruchi Yatoo, Mohd. Iqbal Patel, Shailesh Kumar Pathak, Mamta Malik, Yashpal Singh Dhama, Kuldeep Singh, Karam Pal Bonilla-Aldana, D. Katterine Haque, Shafiul Martinez-Pulgarin, Dayron F. Rodriguez-Morales, Alfonso J. Leblebicioglu, Hakan
Abstract	A novel coronavirus (SARS-CoV-2), causing an emerging coronavirus disease (COVID-19), first detected in Wuhan City, Hubei Province, China, which has taken a catastrophic turn with high toll rates in China and subsequently spreading across the globe. The rapid spread of this virus to more than 210 countries while affecting more than 25 million people and causing more than 843,000 human deaths, it has resulted in a pandemic situation in the world. The SARS-CoV-2 virus belongs to the genus Betacoronavirus, like MERS-CoV and SARS-CoV, all of which originated in bats. It is highly contagious, causing symptoms like fever, dyspnea, asthenia and pneumonia, thrombocytopenia, and the severely infected patients succumb to the disease. Coronaviruses (CoVs) among all known RNA viruses have the largest genomes ranging from 26 to 32 kb in length. Extensive research has been conducted to understand the molecular basis of the SARS-CoV-2 infection and evolution, develop effective therapeutics, antiviral drugs, and vaccines, and to design rapid and confirmatory viral diagnostics as well as adopt appropriate prevention and control strategies. To date, August 30, 2020, no effective, proven therapeutic antibodies or specific drugs, and vaccines have turned up. In this review article, we describe the underlying molecular organization and phylogenetic analysis of the coronaviruses, including the SARS-CoV-2, and recent advances in diagnosis and vaccine development in brief and focusing mainly on developing potential therapeutic options that can be explored to manage this pandemic virus infection, which would help in valid countering of COVID-19.
Related Links	https://ann-clinmicrob.biomedcentral.com/counter/pdf/10.1186/s12941-020-00384-w.pdf
Ending Page	37
Page Count	37
Starting Page	1
File Format	HTM / HTML
ISSN	14760711
DOI	10.1186/s12941-020-00384-w
Journal	Annals of Clinical Microbiology and Antimicrobials
Issue Number	1
Volume Number	19
Language	English
Publisher	BioMed Central
Publisher Date	2020-09-02
Access Restriction	Open
Subject Keyword	Medical Microbiology Infectious Diseases Drug Resistance Microbial Genetics and Genomics Biochemistry Parasitology SARS-CoV-2 COVID-19 Immunotherapeutics Therapeutics Vaccines
Content Type	Text
Resource Type	Review
Subject	Microbiology (medical) Infectious Diseases
Journal Impact Factor	4.6/2023
5-Year Journal Impact Factor	5.3/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19

Repurposing of antibiotics for clinical management of COVID-19: a narrative review

The efficacy and effectiveness of COVID-19 vaccines around the world: a mini-review and meta-analysis

COVID-19 vaccine development: What lessons can we learn from TB?

Changes in the spatial distribution of COVID-19 incidence in Italy using GIS-based maps

MERS-CoV: epidemiology, molecular dynamics, therapeutics, and future challenges

The evaluation of SARS-CoV-2 mutations at the early stage of the pandemic in Istanbul population

SABRes: in silico detection of drug resistance conferring mutations in subpopulations of SARS-CoV-2 genomes

Contrasting SARS-CoV-2 RNA copies and clinical symptoms in a large cohort of Colombian patients during the first wave of the COVID-19 pandemic

SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic

Similar Documents

Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19

Repurposing of antibiotics for clinical management of COVID-19: a narrative review

The efficacy and effectiveness of COVID-19 vaccines around the world: a mini-review and meta-analysis

COVID-19 vaccine development: What lessons can we learn from TB?

Changes in the spatial distribution of COVID-19 incidence in Italy using GIS-based maps

MERS-CoV: epidemiology, molecular dynamics, therapeutics, and future challenges

The evaluation of SARS-CoV-2 mutations at the early stage of the pandemic in Istanbul population

SABRes: in silico detection of drug resistance conferring mutations in subpopulations of SARS-CoV-2 genomes

Contrasting SARS-CoV-2 RNA copies and clinical symptoms in a large cohort of Colombian patients during the first wave of the COVID-19 pandemic

SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic